Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?

The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavaco, Marco, Gaspar, Diana, ARB Castanho, Miguel, Neves, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023012/
https://www.ncbi.nlm.nih.gov/pubmed/31940974
http://dx.doi.org/10.3390/pharmaceutics12010062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023012/
https://www.ncbi.nlm.nih.gov/pubmed/31940974
http://dx.doi.org/10.3390/pharmaceutics12010062

Ejemplares similares